Literature DB >> 16028101

Analysis of cytotoxicities of platinum compounds.

Jerry Goodisman1, Douglas Hagrman, Kirk A Tacka, Abdul-Kader Souid.   

Abstract

Extent of DNA platination, loss of cell viability, DNA fragmentation, and impairment of cellular mitochondrial oxygen consumption are measures of drug cytotoxicity. We measured and compared these effects for cisplatin, oxaliplatin and carboplatin. Because reaction with intracellular thiols may be responsible for drug resistance, we also determined the rates of Pt drug reactions with metallothionein. Jurkat cells were exposed at 37 degrees C to 25 microM Pt drugs for 3 h. Pt-DNA adducts were determined at the end of the incubation period by atomic absorption spectroscopy. Viability, DNA fragmentation, and cellular respiration (microM O2/min/10(6) cells) were determined 24 h post drug exposure. The average amount of Pt-DNA adducts (Pt atoms/10(6) nucleotides) produced by cisplatin was 43.4, by oxaliplatin 4.8 and by carboplatin 1.5. Cisplatin decreased the rate of respiration by approximately 63% and oxaliplatin by approximately 37%. DNA fragmentation by cisplatin and oxaliplatin was very similar. Carboplatin produced an unnoticeable effect on cellular respiration, and only approximately 10% of the DNA fragmentation was produced by cisplatin or oxaliplatin. Although, for a given drug, all four measures of cytotoxicity were proportional, this did not hold for comparisons between the drugs. The rate constants (M-1 s-1) for reaction of cisplatin, oxaliplatin and carboplatin with Cd/Zn thionein were 0.75, 0.44 and 0.012, respectively. For comparison, the rate constants (M-1 s-1) for reaction of cisplatin, oxaliplatin and carboplatin with glutathione were 0.027, 0.038 and 0.0012, respectively. The low reactivity of carboplatin with metallothionein and glutathione suggests that its low cytotoxic activities are not due to reaction of Pt2+ with cellular thiols. Despite a tenfold difference in Pt-DNA adducts between cisplatin and oxaliplatin, the cytotoxicities of these compounds are very similar, suggesting that oxaliplatin lesions are more potent than cisplatin lesions. The results demonstrate a large influence of the ligands occupying Pt coordination spheres on the chemical and biologic activities of Pt drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028101     DOI: 10.1007/s00280-005-0041-4

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

Review 1.  Binding of kinetically inert metal ions to RNA: the case of platinum(II).

Authors:  Erich G Chapman; Alethia A Hostetter; Maire F Osborn; Amanda L Miller; Victoria J DeRose
Journal:  Met Ions Life Sci       Date:  2011

2.  Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.

Authors:  Thomas J Preston; Jeffrey T Henderson; Gordon P McCallum; Peter G Wells
Journal:  Mol Cancer Ther       Date:  2009-06-30       Impact factor: 6.261

3.  Current advances in DNA repair: regulation of enzymes and pathways involved in maintaining genomic stability.

Authors:  Tracy M Neher; John J Turchi
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

4.  In vitro effects of platinum compounds on renal cellular respiration in mice.

Authors:  Saeeda-S Almarzooqi; Ali-S Alfazari; Hidaya-M Abdul-Kader; Dhanya Saraswathiamma; Alia-S Albawardi; Abdul-Kader Souid
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.

Authors:  Elizabeth K Joseph; Jon D Levine
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

6.  A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Authors:  Si-Si Wang; Maike Zimmermann; Hongyong Zhang; Tzu-Yin Lin; Michael Malfatti; Kurt Haack; Kenneth W Turteltaub; George D Cimino; Ralph de Vere White; Chong-Xian Pan; Paul T Henderson
Journal:  Int J Cancer       Date:  2017-05-15       Impact factor: 7.396

7.  Epithelial Ovarian Cancer and Cancer Stem Cells.

Authors:  Amr A Soliman; Alaa A Elzarkaa; Eduard Malik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

10.  Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.

Authors:  Francesca Ricci; Alessandro Corbelli; Roberta Affatato; Rosaria Chilà; Michela Chiappa; Laura Brunelli; Robert Fruscio; Roberta Pastorelli; Fabio Fiordaliso; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.